28 April 2010
The relative toxicity of compounds used as preservatives in vaccines and biologics
David A. GeierABCDEFG, Sarah K. JordanBE, Mark R. GeierABCDEFGMed Sci Monit 2010; 16(5): SR21-27 :: ID: 878526
Abstract
Background
In vaccines/biologics, preservatives are used to prevent microbial growth.
Material and Method
The present study examined: (1) the comparative toxicities of commonly used preservatives in US licensed vaccines to human neurons; and (2) the relative toxicity index of these compounds to human neurons in comparison to bacterial cells.
Results
Using human neuroblastoma cells, the relative cytotoxicity of the levels of the compounds commonly used as preservative in US licensed vaccines was found to be phenol <2-phenoxyethanol < benzethonium chloride < Thimerosal. The observed relative toxicity indices (human neuroblastoma cells/bacterial cells) were 2-phenoxyethanol (4.6-fold) < phenol (12.2-fold) < Thimerosal (>330-fold). In addition, for the compounds tested, except for 2-phenoxyethanol, the concentrations necessary to induce significant killing of bacterial cells were significantly higher than those routinely present in US licensed vaccine/biological preparations.
Conclusions
None of the compounds commonly used as preservatives in US licensed vaccine/biological preparations can be considered an ideal preservative, and their ability to fully comply with the requirements of the US Code of Federal Regulations (CFR) for preservatives is in doubt. Future formulations of US licensed vaccines/biologics should be produced in aseptic manufacturing plants as single dose preparations, eliminating the need for preservatives and an unnecessary risk to patients.
Keywords: Preservatives, Pharmaceutical - adverse effects, Cell Survival - drug effects, Escherichia coli - drug effects, Biological Products - adverse effects, Vaccines - adverse effects
Editorial
01 March 2024 : Editorial
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-ThalassemiaDOI: 10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
In Press
08 Feb 2024 : Database Analysis
Comparative Accuracy of Intraoral and Extraoral Digital Workflows for Short Span Implant Supported Fixed Pa...Med Sci Monit In Press; DOI: 10.12659/MSM.943706
08 Feb 2024 : Clinical Research
Serum Selenium Concentration as a Potential Diagnostic Marker for Early-Stage Colorectal Cancer: A Comparat...Med Sci Monit In Press; DOI: 10.12659/MSM.942882
09 Feb 2024 : Clinical Research
Factors Influencing the Occurrence of Intraoperative Hypothermia in Patients Undergoing General Anesthesia ...Med Sci Monit In Press; DOI: 10.12659/MSM.943463
13 Feb 2024 : Clinical Research
A Retrospective Study to Compare the Glasgow Coma Score, Pediatric Trauma Score, and Injury Severity Score ...Med Sci Monit In Press; DOI: 10.12659/MSM.943501
Most Viewed Current Articles
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952